As many as 96 percent of those infected with COVID-19 retain protective antibodies for at least nine months after confirmed infection. This is shown by a study from Danderyd Hospital
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
The COVID-19 pandemic
In December 2020, SciLifeLab and the Knut and Alice Wallenberg Foundation (KAW), announced a call for a national program studying the effects of COVID-19 vaccines. 24 proposals were submitted and
The company’s qDBS dried blood spot system for home sample collection is being used in a nation-wide randomized clinical trial on the role of Vitamin D in COVID-19 run by
A joint project by VTT, the Tampere University and THL has studied the mechanisms of the droplet and aerosol transmission of COVID-19 and the methods for reducing the risk of
Johnson & Johnson has announced that Janssen-Cilag International has submitted a conditional Marketing Authorization Application (cMAA) to the European Medicines Agency (EMA) seeking authorization for its investigational single-dose Janssen COVID-19
AstraZeneca’s COVID-19 vaccine has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals 18 years of age and older,
The Ministry of Healthcare of Republic of Azerbaijan granted an approval to conduct clinical trials of the combined use of the Sputnik V and the COVID 19 vaccine AstraZeneca in Azerbaijan. Previously, the
NLS News
Philadelphia has a long legacy of life sciences and success and now, cell and gene therapy is fast becoming a local specialty. Mention Philadelphia, Pennsylvania, in the U.S., and the
The DKK 200 million investment will be used to establish the Novo Nordisk Network for Healthy Populations. The network will focus on new ways to support healthier urban populations and
Xbrane Biopharma has entered into a non-binding term-sheet with NewFaDem for a divestment of Primm Pharma. Xbrane’s long term focus is to become a world leading biosimilar developer, and hence
The agreement gives BTC Health, through its investment company BioImpact Pty Ltd, exclusive rights to distribute NEOLA within Australia, New Zealand, Singapore and select countries in the Pacific, as soon
Pre Diagnostics has announced that its PreADx immunoassay for early detection of Alzheimer’s Disease has successfully completed a clinical evaluation. The company now plans to further optimize the assay in
The company plans to in particular use the funds to prepare a clinical trial of their anti-FcγRIIB antibody BI-1206 for the treatment of Non-Hodgkin’s Lymphoma. The Board of Directors of
AstraZeneca has announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was made
The European Medicines Agency Committee for Orphan Medicinal Products (COMP) has issued a positive opinion on the company’s application for orphan designation status for its Phase II clinical candidate, ilixadencel,
Cellink has entered into an agreement with the shareholders of Ginolis to acquire all shares for a purchase price on cash- and debt-free basis of EUR 70 million. Ginolis is
Atlas Antibodies has signed an agreement to acquire UK company HistoCyte Laboratories Ltd. HistoCyte Laboratories’ portfolio of cell line materials provides control of immuno-histochemical assays used in the diagnosis of
The aim of the new award is to celebrate people from KTH who, with their innovations, have contributed to a better society. The monetary award is 500,000 Swedish crowns (EUR
The extension round was led by Industrifonden followed by SEB Greentech VC and existing shareholders. “EnginZyme is demonstrating its ability to replace traditional, fossil fuel-based, energy-intensive, unsustainable chemical production with
Swedish biotech company Salipro Biotech has announced that the European Patent Office has issued the European Patent titled “Saposin lipoprotein particles and libraries from crude membranes”. The patent covers the
Pilloxa has announced the start of a single-armed and multicenter observational clinical trial in which their digital patient-centric adherence solution will be tested in patients with cardiovascular disease, namely newly
Drug and device development
Ultimovacs will participate in the Phase II DOVACC collaboration study with the Nordic Society of Gynaecological Oncology – Clinical Trial Unit (NSGO-CTU), the European Network of Gynaecological Oncological Trial Groups
XNK Therapeutics is entering into a Phase II clinical study to treat patients with multiple myeloma using its leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa. XNK and
Diaprost has announced a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates. The extensive
Ultimovacs has announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the company’s Tetanus-Epitope Targeting (TET)-platform. The platform allows
Nordic Nanovector provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin in 3rd-line relapsed/refractory follicular lymphoma. Despite COVID has the company seen a significant improvement in the
Profile
What began as a project for Evelina Vågesjö’s doctoral thesis grew into groundbreaking drug candidates and delivery methods, followed not long afterwards, by a clinical-stage biopharmaceutical company. Fascinated by the
In a new job
During 2020, the COVID-19 pandemic has caused many previously office-based employees to begin to work from home. Whilst working remotely is seen by some as a temporary measure, others suggest
More than 100 qualified candidates have been screened before the Board of Directors decided to offer Mads Krogsgaard Thomsen the position. “Mads is one of the most competent and committed
The Center for Translational Research Sweden (CTR) has announced that the Board has appointed Karin Meyer as their new Chief Executive Officer. Karin Meyer succeeds Mats Lindquist who has been
Careers
Anna-Leena Saarela is an expert in pharmacovigilance and she sees it as a privilege to work in the front line of this fast developing environment for the benefit of patient
Read the latest issue of our magazine!
No 04 2020 // This issue includes an exclusive interview with Evelina Vågesjö, co-founder and CEO of Ilya Pharma, who turned her thesis project into a successful company. Nordic venture capitalists share their perspectives and advice when it comes to raising capital and we take a closer look at the life science industry in Philadelphia, US, where cell and gene therapy is fast becoming a local specialty.
You may also learn more about having a career within clinical research and what to consider when the Medical Device Directive is replaced by the Medical Device Regulation. Scientists in Finland have found a new piece in the Parkinson’s puzzle and SwedenBIO shares their thoughts on how we can secure the right expertise in the future.
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
The fifteenth annual BIO-Europe Spring partnering conference will be held March 22-25 in a fully digital format. The event will include on-demand early access to the company pitches, program sessions,
NLSDays is the largest Nordic partnering conference dedicated to the life science industry. The 2020 event has been postponed until the 2021 event, April 20-23 2021, delivered digitally. Since its
This event is arranged 2 days in-person and 3 days virtually. This year’s hybrid event enables you to identify, meet and network with leaders across the life science value chain.
Anglonordic is the only life science conference in the UK exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. This one
The latest research news from the Nordic region
Science Article
By sequencing the germline genomes of twins and comparing them to those of close relatives, scientists at deCODE genetics have found mutations that are present in just one of the
When Françoise Barré-Sinoussi came to Stockholm to receive the Nobel Prize in Physiology or Medicine in 2008, she felt like she was in another world. As a true scientist, her
An international collaboration project to develop and implement novel genome-based disease prediction tools has received over 10 million euros from the EU Horizon 2020 Research and Innovation program. The project
In a new study, researchers at Karolinska Institutet have used a urine test to identify and verify a patient’s type of asthma. The study, which has been published in the
The Swedish-Danish type 1 diabetes project DiaUnion has received an additional EUR 1 million funding to investigate the link between type 1 diabetes and related autoimmune diseases. Type 1 diabetes
Biomedicum in Stockholm, designed by C.F. Møller Architects for Akademiska Hus and Karolinska Institutet, is a European Union Prize for Contemporary Architecture – Mies van der Rohe Award 2022 nominee.
Nordic Life Science
The latest clinical trials
XNK Therapeutics is entering into a Phase II clinical study to treat patients with multiple myeloma using its leading drug candidate in combination with Sanofi’s anti-CD38 antibody Sarclisa. XNK and
Diaprost has announced a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates. The extensive
Ultimovacs has announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the company’s Tetanus-Epitope Targeting (TET)-platform. The platform allows
Nordic Nanovector provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin in 3rd-line relapsed/refractory follicular lymphoma. Despite COVID has the company seen a significant improvement in the
Gedea Biotech has enrolled the first patient in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind
Pilloxa has announced the start of a single-armed and multicenter observational clinical trial in which their digital patient-centric adherence solution will be tested in patients with cardiovascular disease, namely newly
As many as 96 percent of those infected with COVID-19 retain protective antibodies for at least nine months after confirmed infection. This is shown by a study from Danderyd Hospital
Gesynta Pharma has announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis. Systemic sclerosis is
Nanoform has announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful, states the company in its press release. Phase
Sign up to our newsletter